Date | Compound | Laboratory | Indication | Type of Information |
---|---|---|---|---|
2013-01-22 | cell based product (donor T lymphocytes depleted ex vivo of host alloreactive T cells using photodynamic treatment) | Kiadis Pharma (The Netherlands) |
|
Granting of a patent |
2013-01-23 | therapeutic vaccine candidate for the treatment of nicotine addiction | Cytos Biotechnology (Switzerland) | nicotine addiction | |
2013-01-23 | AllerT | Anergis (Switzerland) | birch pollen allergy |
Granting of a patent |
2013-01-24 | imatinib mesilate | Novartis (Switzerland) | pulmonary arterial hypertension (PAH) | |
2013-01-30 | bevacizumab | Roche (Switzerland) | combination with fluoropyrimidine-irinotecan or fluoropyrimidine-oxaliplatin based chemotherapy for the second line treatment of patients with metastatic colorectal cancer who have progressed on a first-line Avastin®-containing regimen | Granting of a Market Authorisation in the US |
2013-01-30 | olodaterol | Boehringer Ingelheim (Germany) | chronic obstructive pulmonary disease (COPD) | |
2013-01-31 | exon 44 specific phosphorothioate oligonucleotide | Prosensa (The Netherlands) | Duchenne muscular dystrophy | |
2013-02-07 | immunotherapy tablet | Merck&Co (USA) ALK Abello (Denmark) | grass pollen allergy |
Refiling of a Market Application in the USA |
2013-02-07 | polidocanol endovenous microfoam (PEM) | BTG International (UK) | varicose veins | |
2013-02-07 | asunercept | Apogenix (Germany) | myelodysplastic syndromes | Granting of a patent |
2018-07-26 | trametinib in combination with dabrafenib | Novartis (Switzerland) |
|
Positive opinion for the granting of a Market Authorisation in the EU |
2013-02-13 | pomalidomide | Celgene (USA) | multiple myeloma |
Granting of a Market Authorisation in the EU |
2012-06-15 | ferumoxytol | Takeda Pharmaceutical (Japan) AMAG Pharmaceuticals (USA) | iron deficiency anaemia in adult patients with chronic kidney disease |
Granting of a Market Authorisation in the EU |
2013-02-14 | defactinib - N-methyl-4-({4-[({3-methyl(methylsulfonyl)amino]pyrazin-2-yl}methyl)amino]-5-(trifluoromethyl)pyrimidin-2-yl}amino)benzamide hydrochloride | Verastem (USA - CA) | mesothelioma |
Granting of the orphan status in the EU |
2013-02-14 | antibody platform | MorphoSys (Germany) | Granting of a patent | |
2013-02-14 | 4-[2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-quinoline-6-carboxamide monohydrate | Eli Lilly (USA) | hepatocellular carcinoma | |
2013-02-14 | murine IgM monoclonal antibody binding to alpha beta T-cell receptor | CTI Clinical Trial and Consulting Services (USA) | prevention of graft rejection following solid organ transplantation | |
2013-02-14 | poloxamer 188 | Theradex Europe (UK) | sickle cell disease | |
2013-02-14 | recombinant human heat shock protein 70 | Orphazyme (Denmark) | Niemann-Pick disease, type C | |
2013-02-14 | cyclo[L-alanyl-L-seryl-L-isoleucyl-L-prolyl-L-prolyl-L-glutaminyl-L-lysyl-L-tyrosyl-D-prolyl-L-prolyl-(2S)-2-aminodecanoyl-L-alpha-glutamyl-L-threonyl] acetate salt | Polyphor UK (UK) | congenital alpha-1 antitrypsin deficiency | Granting of the orphan status in the EU |
© 2024 Biopharmanalyses - Powered by Samacom+